176 related articles for article (PubMed ID: 19075965)
1. Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review.
Toussirot E; Streit G; Wendling D
Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):39-47. PubMed ID: 19075965
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
3. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
4. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
5. [Safety of anti-TNFα biological drugs].
Trotta F; Valentini G
Reumatismo; 2005; 57(4 Suppl):34-9. PubMed ID: 16385354
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance.
Cantini F; Niccoli L; Goletti D
J Rheumatol Suppl; 2014 May; 91():47-55. PubMed ID: 24789000
[TBL] [Abstract][Full Text] [Related]
7. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
9. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
[TBL] [Abstract][Full Text] [Related]
10. [Tuberculosis during treatment by TNFalpha-inhibitors].
Strady C; Brochot P; Ainine K; Jegou J; Remy G; Eschard JP; Jaussaud R
Presse Med; 2006 Nov; 35(11 Pt 2):1765-1772. PubMed ID: 17086139
[TBL] [Abstract][Full Text] [Related]
11. TNFalpha as therapeutic target: new drugs, more applications.
Reimold AM
Curr Drug Targets Inflamm Allergy; 2002 Dec; 1(4):377-92. PubMed ID: 14561184
[TBL] [Abstract][Full Text] [Related]
12. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
Ford AC; Peyrin-Biroulet L
Am J Gastroenterol; 2013 Aug; 108(8):1268-76. PubMed ID: 23649185
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events.
Murdaca G; Colombo BM; Puppo F
Int J Immunopathol Pharmacol; 2009; 22(3):557-65. PubMed ID: 19822072
[TBL] [Abstract][Full Text] [Related]
15. Problems encountered during anti-tumour necrosis factor therapy.
Desai SB; Furst DE
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
Cantini F; Niccoli L; Goletti D
J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
[TBL] [Abstract][Full Text] [Related]
18. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
19. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
[TBL] [Abstract][Full Text] [Related]
20. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
